Tesla Diagnostix
Lab-on-chip diagnostic platforms and point-of-care medical devices for healthcare testing
Highlights
- Young companyFounded 2022
- New on EvolcAdded 2026-11-07
About Tesla Diagnostix
Tesla Diagnostix develops small diagnostic platforms for fast results at the point of care. Its technology integrates laboratory processes onto a miniaturized chip or printed circuit board, with single-use medical devices intended to replace some laboratory-based tests.
The company is based in Bristol, United Kingdom, and was founded in 2022.
Product: Lab-on-chip diagnostic platforms and single-use point-of-care medical devices.
Jobs at Tesla Diagnostix
More health & medtech companies
Testcard
Digital diagnostic testing and at-home test kits for healthcare providers, research organisations and consumersNew on EvolcTFP Fertility Group
Fertility clinics providing IVF and other reproductive treatments to patients in the UK and PolandNew on Evolcthameshospice.org.uk
Free palliative and end-of-life care for patients and families across East Berkshire and South BuckinghamshireNew on EvolcSalary transparentThe Allergy Team
Allergy training, resources and support for schools, families, healthcare providers and businessesNew on EvolcThe Beeches UK
Residential childcare, supported living and specialist education for young people with autism, learning difficulties and complex needsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
